• Vicore Pharma filed a registration statement with the U.S. SEC as it pursues a dual listing for its American Depositary Receipts on Nasdaq in the United States.
• The ordinary shares would continue to trade on Nasdaq Stockholm if the U.S. listing proceeds.
• The ADR listing remains subject to SEC review and Nasdaq’s decision on the company’s listing application.
• No concurrent financing or new share issue is planned in connection with the proposed dual listing.
• The move comes as the company heads toward a mid-2027 readout from its Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vicore Pharma Holding AB published the original content used to generate this news brief on May 22, 2026, and is solely responsible for the information contained therein.